Lilly, Zeneca Drugs to Be Part of U.S. Cancer Prevention study
Washington, Oct. 21 (Bloomberg) -- Drugs sold by Eli Lilly &
Co. and Zeneca Group Plc will be part of the largest-ever breast
cancer prevention study, U.S. officials said.
The 20,000-patient trial, known as the Study of Tamoxifen
and Raloxifene, or STAR, is awaiting approval by the U.S. Food
and Drug Administration. If the FDA approves plans for the study,
it will begin next year and take place in 400 sites around the
U.S.
First Lady Hillary Clinton announced the study during an
event at the White House at which both she and President Bill
Clinton lauded recent advancements in breast cancer research and
prevention.
''I believe that we are within reach of genuine cures and
genuine prevention strategies of stunning impact,'' the president
said.
Neither Zeneca's tamoxifen nor Lilly's raloxifene is
approved for breast cancer prevention.
U.K.-based Zeneca, the world's No. 2 cancer drugmaker, is
seeking approval of tamoxifen, also known as Nolvadex, for
prevention of breast cancer in high-risk women. The drug was
shown to lower the incidence of breast cancer in a landmark study |
